Akoya Biosciences (AKYA) Stock Price, News & Analysis

Company Overview

Founded in 2016 and headquartered in Menlo Park, California, Akoya Biosciences is a global leader in spatial biology solutions designed to accelerate the discovery and development of novel therapeutics. The company’s core mission is to provide researchers and pathologists with the tools necessary to visualize and quantify the spatial relationships of proteins, RNA, and other biomarkers in intact tissues, advancing our understanding of complex diseases such as cancer and autoimmune disorders.

Akoya’s product portfolio includes the CODEX (CO-Detection by indEXing) system, which enables highly multiplexed, single-cell imaging of formalin-fixed, paraffin-embedded (FFPE) and fresh-frozen tissue sections. The company also offers the Phenoptics line of immunofluorescence and chromogenic imaging platforms, accompanied by proprietary reagents and software analytics. These integrated solutions support both discovery research and translational studies, facilitating everything from early-stage biomarker identification to companion diagnostic development.

Serving a diverse clientele across academic institutions, pharmaceutical and biotechnology companies, and contract research organizations, Akoya maintains operations in North America, Europe, and the Asia-Pacific region. The company’s global reach is reinforced by strategic partnerships and distribution agreements, ensuring its technologies are accessible to a broad scientific community. Akoya’s instruments and assays have been utilized in hundreds of research publications, underscoring their impact on the life sciences field.

Akoya is led by an experienced management team with deep expertise in life sciences instrumentation and imaging technologies. The leadership group includes veterans from the biotech and pharmaceutical industries, supported by a board of directors committed to driving growth through innovation and customer-centric solutions. Under this guidance, Akoya continues to expand its product offerings and deepen its footprint in the burgeoning spatial biology market.

Key Stats

• Today's Range: $1.29 to $1.29
• 50-Day Range: $0.95 to $1.37
• 52-Week Range: $0.93 to $3.42
• Volume: N/A
• Average Volume: 409,353 shs
• Market Capitalization: $64.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.51
• Consensus Rating: Hold

Akoya Biosciences Stock Analysis - MarketRank™

Akoya Biosciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 763rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Akoya Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Akoya Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Akoya Biosciences are expected to grow in the coming year, from ($0.96) to ($0.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akoya Biosciences is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akoya Biosciences is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Akoya Biosciences has a P/B Ratio of 8.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.67% of the float of Akoya Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Akoya Biosciences has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Akoya Biosciences has recently decreased by 7.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akoya Biosciences does not currently pay a dividend.

Dividend Growth

Akoya Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.67% of the float of Akoya Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Akoya Biosciences has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Akoya Biosciences has recently decreased by 7.04%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.93

News Sentiment

Akoya Biosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Akoya Biosciences this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Akoya Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of Akoya Biosciences is held by insiders.

Percentage Held by Institutions

79.42% of the stock of Akoya Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AKYA Stock Analysis - Frequently Asked Questions

How have AKYA shares performed this year?

Akoya Biosciences' stock was trading at $2.29 on January 1st, 2025. Since then, AKYA stock has decreased by 43.7% and is now trading at $1.29.

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) announced its earnings results on Monday, May, 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.03. The business earned $16.64 million during the quarter, compared to analysts' expectations of $20.19 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 487.85% and a negative net margin of 59.44%.

When did Akoya Biosciences IPO?

Akoya Biosciences (AKYA) raised $125 million in an initial public offering on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO.

How do I buy shares of Akoya Biosciences?

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Akoya Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akoya Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AKYA
• CIK: 1711933
• Web: www.akoyabio.com
• Phone: 855-896-8401
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Akoya Biosciences: $2.51
• High Price Target: $5.00
• Low Price Target: $1.08
• Potential Upside/Downside: +94.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.37 million
• Net Margins: -59.44%
• Pretax Margin: -59.28%
• Return on Equity: -487.85%
• Return on Assets: -35.86%

Debt

• Debt-to-Equity Ratio: 10.12
• Current Ratio: 0.61
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: $79.96 million
• Price / Sales: 0.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 8.60

Miscellaneous

• Outstanding Shares: 49,954,000
• Free Float: 46,307,000
• Market Cap: $64.44 million
• Optionable: Optionable
• Beta: 1.36